Patrice, Carter
Ahmet, Fuat
Sylvia, Haas
Elizabeth, Smyth
Carlos, Brotons
Frank, Cools
Rupert, Bauersachs
Richard, Hobbs F. D.
Funding for this research was provided by:
Bristol-Myers Squibb, Pfizer Alliance
Article History
Received: 9 November 2022
Accepted: 16 February 2024
First Online: 18 March 2024
Declarations
:
: We completed the Health Research Authority (HRA) and UK Medical Research Council (MRC) decision tool to determine that this research did not require ethics committee approval (ExternalRef removed). The NHS HRA and UK MRC have the authority to waiver such studies from ethics committee approval; the NHS HRA and UK MRC deemed ethics approval was not necessary for our study according to their legislation. [CitationRef removed, CitationRef removed]. All participants were made aware their participation was voluntary, were informed of the study purpose, risks and benefits and provided informed consent to participate. Participants were also made aware their responses were anonymous and they could withdraw at any time. We conducted the study according to the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines as appropriate.
: Not applicable.
: PC is an employee of HEOR Ltd who were paid consultants to Bristol Myers Squibb and Pfizer in connection with the development of this manuscript AF has received honoraria for lectures given for Bayer, Daiichi-Sanyko, Pfizer/BMS and Boehringer-Ingelheim. SH has received personal fees from Bayer, BMS, Daiichi-Sankyo, Pfizer and Sanofi. ES has received consultancy fees from Amal Therapeutics, Aptitude Health, Astellas, AstraZeneca, Beigene, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Roche, Sai-Med, Servier and Zymeworks. ES has also received institutional research support from Astellas, AstraZeneca, Roche, MSD and Basilea. AstraZeneca and BMS. FC has received moderate speaker and consulting fees from Daiichi Sankyo. RB has received personal fees from Bayer, BMS, Daiichi-Sankyo and Pfizer. FDRH has received occasional speaker or consultancy fees from Astra-Zeneca, BI, BMS/Pfizer, Bayer and Novartis. RH has also been awarded institutional research funding from Novartis and AstraZeneca. CB has nothing to declare.